Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion

We assessed whether a panel of seven antibodies is useful in the differentiation of adenocarcinoma cells (ACCs) from reactive mesothelial cells (RMCs) in effusion samples and to determine optimal specimen preparation conditions for immunocytochemical analysis of effusion samples. Immunocytochemistry (ICC) was performed on three types of effusion preparations from the same effusion specimens: ethanol‐fixed smears, ethanol‐fixed cell ‐blocks, and formalin‐fixed cell‐blocks. Commercially available antibodies MOC‐31, Ber‐EP4, CA19‐9, CEA, EMA, CA125, and HBME‐1 were tested on RMCs from four samples of various etiology and 15 samples of adenocarcinoma from various primary sites. Ethanol‐fixed smears showed strong immunoreactivity to all antibodies tested. The immunoreactivity of ethanol‐fixed and formalin‐fixed cell‐blocks was significantly lower with all antibodies except CA19‐9. Smear preparations are more sensitive than cell‐blocks for immunocytochemical study. A panel of antibodies MOC‐31, Ber‐EP4, CA19‐9, and CEA appears to be suitable to distinguish between ACCs and RMCs. Diagn. Cytopathol. 2006;34:6–10. © 2005 Wiley‐Liss, Inc.

[1]  Y. Gong,et al.  Immunocytochemistry of serous effusion specimens: A comparison of ThinPrep® vs. cell block , 2003, Diagnostic cytopathology.

[2]  P. Gibson,et al.  GLUT1 Antibody Staining in Thin-Layer Specimens of Benign and Malignant Body Cavity Effusions , 2002, Acta Cytologica.

[3]  A. Simsir,et al.  Comparison of three commonly used cytologic preparations in effusion immunocytochemistry , 2002, Diagnostic cytopathology.

[4]  P. Fetsch,et al.  Immunocytochemistry in effusion cytology , 2001, Cancer.

[5]  M. Lozano,et al.  Immunocytochemistry in the differential diagnosis of serous effusions , 2001, Cancer.

[6]  B. Kendall,et al.  Use of Desmin Immunohistochemistry To Distinguish Between Mesothelial Cells and Carcinoma in Serous Fluid Cell Block Preparations , 2000, Acta Cytologica.

[7]  Edwards,et al.  HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma , 2000, Histopathology.

[8]  Y. Inayama,et al.  Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma , 2000, Cancer.

[9]  A. Hjerpe,et al.  Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis , 2000, Cytopathology : official journal of the British Society for Clinical Cytology.

[10]  B. D. De Young,et al.  MOC‐31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells , 1999, Cancer.

[11]  N. Ordóñez.  Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. , 1999, American journal of clinical pathology.

[12]  A. Berner,et al.  Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies , 1999, Virchows Archiv.

[13]  P. Fetsch,et al.  Utility of the antibodies CA 19‐9, HBME‐1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology , 1998, Cancer.

[14]  J. Riera,et al.  The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. , 1997, The American journal of surgical pathology.

[15]  T. H. van der Kwast,et al.  Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions , 1997, Diagnostic cytopathology.

[16]  M. C. Lee,et al.  Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions. , 1996, Acta cytologica.

[17]  N. Mulvany.  Cytohistologic correlation in malignant peritoneal washings. Analysis of 75 malignant fluids. , 1996, Acta cytologica.

[18]  W. Mccarthy,et al.  Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[19]  H. Stein,et al.  Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. , 1990, Journal of clinical pathology.